Alberto Pavan

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso et al. · The Oncologist · 2019 · 228 citations

Medicine, Immunology, Oncology +17

The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes

Laura Bonanno, Alberto Pavan, Maria Vittoria Dieci et al. · European Journal of Cancer · 2018 · 114 citations

Medicine, Immunology, Oncology +17

Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time

Giulia Pasello, Giulia Zago, Francesca Lunardi et al. · Annals of Oncology · 2018 · 105 citations · Full text

Medicine, Oncology, Pathology +17

First-Line Osimertinib in Patients with <i>EGFR</i>-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study

M. Lorenzi, Alessandra Ferro, Fabiana Letizia Cecere et al. · The Oncologist · 2021 · 62 citations · Full text

Medicine, Oncology, Pharmacology +15

Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer

Elisabetta Zulato, Ilaria Attili, Alberto Pavan et al. · British Journal of Cancer · 2020 · 46 citations · Full text

Medicine, Molecular Genetics, Oncology +17